We are pleased to welcome AbbVie as our new associated partner !
Since AbbVie's launch in 2013, the company has invested ~$50 billion in research to discover, develop and deliver new medicines. AbbVie's main target is diseases with significant unmet need where it can improve the standard of care with innovative new therapies.
Today, AbbVie has ~50,000 employees around the world focus on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women’s health, as well as through our Allergan Aesthetics portfolio.
We are happy and proud to count AbbVie among our partners.